Compare NXL & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXL | ADIL |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.3M |
| IPO Year | 2022 | 2017 |
| Metric | NXL | ADIL |
|---|---|---|
| Price | $6.73 | $5.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | ★ 139.6K | 75.4K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $301,647.00 | N/A |
| Revenue This Year | $15.52 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 78.78 | N/A |
| 52 Week Low | $0.22 | $0.13 |
| 52 Week High | $7.69 | $6.41 |
| Indicator | NXL | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 96.86 | 65.61 |
| Support Level | $0.44 | $1.63 |
| Resistance Level | N/A | $6.41 |
| Average True Range (ATR) | 0.18 | 0.65 |
| MACD | 0.69 | -0.01 |
| Stochastic Oscillator | 92.77 | 79.73 |
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.